- Home
- HE vs JANX Comparison
HE vs JANX Comparison
Compare HE & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | JANX |
|---|---|---|
| Founded | 1891 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HE | JANX |
|---|---|---|
| Price | $13.64 | $13.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $11.50 | ★ $60.27 |
| AVG Volume (30 Days) | ★ 5.4M | 2.3M |
| Earning Date | 02-20-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $3,080,252,000.00 | $10,000,000.00 |
| Revenue This Year | $12.61 | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $155.05 | ★ N/A |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $8.14 | $13.26 |
| 52 Week High | $13.91 | $61.59 |
Technical Indicators
Market Signals| Indicator | HE | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 68.92 | 31.36 |
| Support Level | $12.21 | $13.26 |
| Resistance Level | $13.91 | $14.30 |
| Average True Range (ATR) | 0.47 | 0.44 |
| MACD | 0.16 | 0.44 |
| Stochastic Oscillator | 88.15 | 51.61 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.